Contact

Our portfolio

Primagen

Primagen Holding focuses on developing molecular diagnostic tests and investing in bio- and medtech startups. The company generates revenues through the licensing of their diagnostics technology. Primagen Holding’s portfolio includes investments in PulseCath and Akkolens International.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Infectious Disease
  • Founding year: 1993
Visit website

Want to get in contact about Primagen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
SigmaScreening
Developing a painless and more accurate mammography technology for breast cancer detection.
Amplio Pharma
Amplifying treatment of chronic autoimmune diseases.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
SigmaScreening
Developing a painless and more accurate mammography technology for breast cancer detection.
Amplio Pharma
Amplifying treatment of chronic autoimmune diseases.
Explore full AAV portfolio
Contact